Literature DB >> 19561451

Rifampin-associated pseudomembranous colitis.

Tun-Chieh Chen1, Po-Liang Lu, Wei-Ru Lin, Chun-Yu Lin, Jeng-Yih Wu, Yen-Hsu Chen.   

Abstract

Pseudomembranous colitis (PMC) is known to develop after antibiotic treatment, but is rarely associated with antituberculosis (anti-TB) agents. We report a 28-year-old woman without underlying diseases developing PMC after 126 days of anti-TB treatment. Severe diarrhea and abdominal cramping pain were experienced. Colonoscopic biopsy proved the diagnosis of PMC. Her symptoms improved after discontinuing the anti-TB agents but recurred shortly after challenging with rifampin and isoniazid. Metronidazole administration and replacement of rifampin with levofloxacin successfully cured the PMC. Our report supports the notion that rifampin can induce PMC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19561451     DOI: 10.1097/MAJ.0b013e31819f1eec

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  4 in total

1.  Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation.

Authors:  Jie Cheng; Yatrik M Shah; Xiaochao Ma; Xiaoyan Pang; Toshiya Tanaka; Tatsuhiko Kodama; Kristopher W Krausz; Frank J Gonzalez
Journal:  J Pharmacol Exp Ther       Date:  2010-07-13       Impact factor: 4.030

2.  Emergence of Clostridium difficile infection in tuberculosis patients due to a highly rifampicin-resistant PCR ribotype 046 clone in Poland.

Authors:  P Obuch-Woszczatyński; G Dubiel; C Harmanus; E Kuijper; U Duda; D Wultańska; A van Belkum; H Pituch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-27       Impact factor: 3.267

3.  Rifampin-induced Pseudomembranous Colitis with Rectosigmoid Sparing.

Authors:  Sun Young Yim; Ja Seol Koo; Ye Ji Kim; Sang Jung Park; Jin Nam Kim; Sung Woo Jung; Hyung Joon Yim; Sang Woo Lee; Jai Hyun Choi; Chang Duck Kim
Journal:  Clin Endosc       Date:  2011-12-31

4.  Incidence and Clinical Outcomes of Clostridium difficile Infection after Treatment with Tuberculosis Medication.

Authors:  Yu Mi Lee; Kyu Chan Huh; Soon Man Yoon; Byung Ik Jang; Jeong Eun Shin; Hoon Sup Koo; Yunho Jung; Sae Hee Kim; Hee Seok Moon; Seung Woo Lee
Journal:  Gut Liver       Date:  2016-03       Impact factor: 4.519

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.